在这个新一轮医改方案中,中小药企可能是利益受影响最大的一方。在医改意见颁布后的这段时间里,有人对药品行业的前景仍然看好,有人一头雾水,感到前途渺茫,有人在其中看到了机遇,有人对企业未来的命运充满着担忧……为此,本刊记者采访了北京市部分中小药品生产企业的负责人,听他们一诉衷肠。 In this new round of medical reform programs, small and medium-sized pharmaceutical companies may be the most affected interests. During the period after the promulgation of the medical reform opinion, some people still have a good prospect for the pharmaceutical industry. Some people are confused and feel the future is uncertain. Some people have seen the opportunity in it and some people are worried about the future destiny of the enterprise ...... Therefore, Our correspondents interviewed some of Beijing’s small and medium-sized drug manufacturers head, listen to them a vindictive.